Your browser is no longer supported. Please, upgrade your browser.
Intersect ENT, Inc.
Index- P/E- EPS (ttm)-1.85 Insider Own2.40% Shs Outstand32.70M Perf Week4.43%
Market Cap750.81M Forward P/E- EPS next Y-1.33 Insider Trans0.00% Shs Float31.68M Perf Month-0.63%
Income-60.10M PEG- EPS next Q-0.32 Inst Own92.10% Short Float2.99% Perf Quarter19.76%
Sales84.10M P/S8.93 EPS this Y-81.10% Inst Trans3.05% Short Ratio4.02 Perf Half Y23.29%
Book/sh2.49 P/B9.57 EPS next Y31.10% ROA-37.90% Target Price23.00 Perf Year-2.10%
Cash/sh4.15 P/C5.74 EPS next 5Y7.60% ROE-60.60% 52W Range5.97 - 26.98 Perf YTD4.02%
Dividend- P/FCF- EPS past 5Y3.20% ROI-38.40% 52W High-11.71% Beta1.65
Dividend %- Quick Ratio7.40 Sales past 5Y23.10% Gross Margin65.70% 52W Low298.99% ATR1.43
Employees402 Current Ratio7.90 Sales Q/Q-5.80% Oper. Margin-70.00% RSI (14)49.67 Volatility6.89% 5.46%
OptionableYes Debt/Eq0.77 EPS Q/Q14.10% Profit Margin-71.50% Rel Volume1.09 Prev Close22.95
ShortableYes LT Debt/Eq0.77 EarningsMar 09 BMO Payout- Avg Volume235.46K Price23.82
Recom2.40 SMA20-1.22% SMA50-0.16% SMA20026.87% Volume256,972 Change3.79%
Jan-11-21Upgrade Canaccord Genuity Hold → Buy $25
Nov-19-20Upgrade BTIG Research Neutral → Buy $32
Oct-08-20Downgrade JP Morgan Overweight → Neutral $19
Aug-07-20Upgrade Guggenheim Neutral → Buy $30
Jun-24-20Initiated Oppenheimer Perform
May-12-20Downgrade Canaccord Genuity Buy → Hold
Apr-15-20Downgrade BofA/Merrill Buy → Underperform $28 → $10
Aug-02-19Downgrade Piper Jaffray Overweight → Neutral $30 → $17
Aug-02-19Downgrade Guggenheim Buy → Neutral
Jul-10-19Upgrade Northland Capital Under Perform → Market Perform $20
Jun-21-19Downgrade Berenberg Buy → Hold
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $29
May-07-19Downgrade Northland Capital Market Perform → Under Perform $28 → $20
Apr-20-18Initiated Berenberg Buy
Jan-02-18Upgrade JP Morgan Neutral → Overweight
May-31-17Downgrade Northland Capital Outperform → Market Perform
May-03-17Reiterated Wedbush Outperform $25 → $26
Dec-07-16Initiated Guggenheim Buy $20
Nov-02-16Downgrade JP Morgan Overweight → Neutral
Oct-06-16Initiated Deutsche Bank Hold $17
Mar-05-21 09:59AM  
Mar-03-21 05:10AM  
Mar-02-21 12:30PM  
Feb-23-21 04:05PM  
Feb-11-21 07:00AM  
Feb-01-21 04:05PM  
Jan-26-21 08:22AM  
Jan-19-21 07:00AM  
Jan-18-21 09:41AM  
Jan-12-21 07:00AM  
Jan-05-21 08:00AM  
Dec-24-20 10:44AM  
Dec-16-20 09:19AM  
Dec-02-20 11:31AM  
Nov-17-20 04:45PM  
Nov-05-20 04:05PM  
Nov-04-20 02:18PM  
Nov-02-20 08:25AM  
Oct-26-20 12:31PM  
Oct-20-20 09:27AM  
Oct-16-20 07:15AM  
Oct-15-20 04:05PM  
Oct-09-20 08:00AM  
Oct-02-20 08:00AM  
Sep-22-20 03:47PM  
Sep-15-20 08:00AM  
Sep-11-20 09:51AM  
Sep-10-20 05:30PM  
Sep-03-20 11:31AM  
Aug-05-20 10:34AM  
Aug-04-20 08:35AM  
Jul-28-20 12:33PM  
Jul-22-20 04:05PM  
Jul-13-20 10:07AM  
Jul-08-20 03:52PM  
Jul-02-20 08:48PM  
Jun-23-20 03:01AM  
Jun-22-20 12:10PM  
Jun-11-20 11:16AM  
Jun-09-20 07:00AM  
Jun-03-20 07:32AM  
May-26-20 04:15PM  
May-14-20 09:28AM  
May-12-20 04:31AM  
May-11-20 08:25AM  
May-08-20 07:00AM  
May-07-20 04:05PM  
May-02-20 09:15AM  
Apr-28-20 04:05PM  
Apr-27-20 12:32PM  
Apr-20-20 09:02AM  
Apr-15-20 08:26AM  
Apr-13-20 04:15PM  
Mar-25-20 11:30AM  
Mar-18-20 05:28PM  
Mar-16-20 09:38AM  
Mar-04-20 09:48AM  
Mar-02-20 08:48AM  
Mar-01-20 10:55AM  
Feb-28-20 08:59AM  
Feb-25-20 09:28AM  
Feb-24-20 08:15AM  
Feb-17-20 12:30PM  
Feb-05-20 04:05PM  
Jan-23-20 10:48AM  
Jan-14-20 05:43AM  
Jan-13-20 10:16AM  
Dec-31-19 10:45AM  
Dec-24-19 11:21AM  
Dec-12-19 10:25AM  
Dec-11-19 04:05PM  
Dec-08-19 07:27PM  
Dec-04-19 04:05PM  
Dec-01-19 09:30AM  
Nov-27-19 07:00AM  
Nov-19-19 04:05PM  
Nov-14-19 01:08PM  
Nov-12-19 08:58AM  
Nov-04-19 09:53AM  
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOLL FREDERIC HDirectorJan 19Option Exercise0.7212,5009,000260,961Feb 05 06:53 PM
West Thomas A.President and CEOMar 17Buy8.4819,035161,434236,890Mar 18 04:59 PM
MEIER RICHARD AEVP & Chief Financial OfficerMar 17Buy7.805,00038,997124,471Mar 17 08:37 PM
MEIER RICHARD AEVP & Chief Financial OfficerMar 16Buy12.5510,000125,462119,471Mar 17 06:02 AM